CATEGORY AND TAGS:
Cagrilintide Peptide raw powder, raw Cagrilintide peptide, Cagrilintide Dosage Dose, buy Cagrilintide 2mg, Cagrilintide 5mg blue top, Cagrilintide 10mg red top, Cagrilintide cycle, Cagrilintide factory price, research chemical Cagrilintide peptide, Cagrilintide 10vials, where to buy Cagrilintide, Cagrilintide peptide supplier, Cagrilintide online store, buy Cagrilintide Canada, Cagrilintide Poland, Cagrilintide USA, human growth peptide Cagrilintide, Cagrilintide manufacturer, Cagrilintide raw powder for sale, Cagrilintide effects, Cagrilintide fat loss
Cagrilintide Specifications
CAS No.: 1415456-99-3
EINECS: 206-141-6
Purity: 99%
Appearance: White powder
Cagrilintide Description
Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia
Cagrilintide Application
Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once-weekly subcutaneous formulation. It is a long-acting amylin analogue. Amylin is co-located with insu in secretory granules and co-secreted with insu by pancreatic beta cells in response to food intake.
CagriSema is a combination medication of the GLP-1 receptor agonist semaglutide and cagrilintide. Cagrilinitide mimics the hormone amylin, which is produced by the pancreas. Together with insu, amylin makes people feel satiated or full after eating a meal.
CagriSema is a once-weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes treatment.